iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)

iCAD implements ProFound AI Detection to improve mammography reading and breast cancer detection in low-resource institutions and medically underserved communities

NASHUA, N.H., April 03, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic global health collaboration with RAD-AID International. RAD-AID, a non-profit charitable organization dedicated to improving radiology healthcare in medically underserved regions, is collaborating with iCAD to introduce mammography AI-based decision support in LMICs, starting with an implementation in Guyana using iCAD’s ProFound Detection.

The partnership’s primary goal is to improve the speed, efficiency and accuracy of breast imaging and breast cancer detection by providing low-resource medical institutions with access to technology, education, clinical support, and hands-on training. iCAD and RAD-AID aim to begin in Guyana where implementation of iCAD’s ProFound AI Detection Solution, coupled with RAD-AID’s educational and capacity-building initiatives, aims to increase, and improve breast cancer detection for patients in need. Such collaboration endeavors to build AI-supported models for globally reducing health care disparities and increasing health equity by widening access to earlier cancer diagnostics.

“Breast cancer remains a significant global health challenge, particularly in regions where trained clinical personnel and technological resources are scarce and drive deep disparities in breast cancer outcomes.” said Daniel Mollura, M.D., RAD-AID Founder and CEO. “By integrating iCAD’s ProFound Detection AI algorithm into mammography workflows in low-resource institutions, along with RAD-AID’s support for radiology education, patient-navigation, and medical imaging capacity-building, we aim to improve early cancer detection and save more lives. We are grateful for this support from iCAD, which advances RAD-AID’s mission to expand health equity for those living and working in medically underserved communities.”

“Dedicated to our mission of creating a world where cancer can’t hide and one where every woman has access to quality care, iCAD is honored to partner with RAD-AID on this transformative program to ensure advances in early cancer detection are available globally,” said Dana Brown, President and CEO of iCAD. “Our deployment of ProFound AI Detection in Guyana represents a significant step forward in the fight against breast cancer in low-resource settings. Together with RAD-AID, we can revolutionize breast cancer detection accuracy and efficiency, ensuring medical professionals have the training and the tools they need to work smarter. When it comes to a cancer diagnosis, we believe where you live should not determine whether you live.”

Both iCAD and RAD-AID will be attending the 2024 SBI Breast Imaging Symposium from April 11-14 at the Palais des Congrès de Montréal (Montréal Convention Centre). The meeting theme is “Reimagining Breast Imaging – Seeing Opportunities Together” which perfectly portrays the essence of this mission-driven partnership.

Connect with us live at SBI – Schedule time to learn about this new partnership via: https://www.icadmed.com/about/news-events/upcoming-tradeshows-and-meetings/sbi-2024/

About RAD-AID International
RAD-AID International is a 501(c)(3) nonprofit organization dedicated to improving and expanding radiology services in under-resourced and medically underserved regions of the world. The World Health Organization (WHO) reports that over half of the world’s population has little or no access to medical imaging (radiology), such as x-ray, ultrasound, fluoroscopy (including diagnostic and interventional radiology), CT, MRI, nuclear medicine, and mammography. To address this worldwide problem, RAD-AID uses a multidisciplinary approach involving infrastructure development, healthcare system expansion, technology innovation, clinical education, and technical training to improve global radiology for delivering vital health services. Learn more at www.rad-aid.org.  

About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com.

Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.


Media inquiries: pr@icadmed.com
Investor Inquiries: ir@icadmed.com

error: Content is protected !!